Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Other material
confidence 72%
filed 2026-06-01
Item 8.01
Oruka entered into a First Amendment to its IL-23 License Agreement with Paragon Therapeutics on May 29, 2026, expanding the Field to include inflammatory bowel disease—a significant therapeutic expansion for the Company's lead candidate ORKA-001. While this is a material licensing amendment affecting the Company's development rights and commercial scope, it does not fit cleanly into the more specific event categories (not an M&A transaction, not a covenant breach, not a restatement or going-concern issue). The expansion of therapeutic indications and the conditional restrictions on dosing timelines represent a material modification to the Company's intellectual property and development strategy.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-01
The filing discloses presentation of clinical data at the American Society of Clinical Oncology Annual Meeting via press release (Item 8.01). For a clinical-stage oncology company, clinical data presentations at major medical conferences are typically material to investors assessing pipeline progress and competitive positioning, though the 8-K itself provides minimal detail. Without access to the actual press release content, the materiality and specific event classification cannot be definitively determined, warranting the broader "other_material" classification.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-01
Item 8.01
The disclosure announces presentation of clinical data at the American Society of Clinical Oncology Annual Meeting by the company's wholly-owned subsidiary Citius Oncology. While clinical data presentations can be material to investors evaluating pipeline progress and competitive positioning, the filing does not specify the nature, significance, or outcomes of the data presented. Without details on efficacy, safety, or regulatory implications, this is best classified as other_material rather than a more specific event type.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-01
Item 8.01
The Company disclosed a $2,000 deposit to extend its business combination deadline from June 2, 2026 to July 2, 2026. This is a material event for a SPAC (special purpose acquisition company) as it signals the Company is actively managing its timeline to complete an initial business combination and avoid liquidation. While not fitting neatly into the standard taxonomy categories, the extension of a critical deadline is material to investors assessing the Company's ability to execute its stated purpose.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-01
Item 1.01
BlockchAIn Digital Infrastructure entered into a 15-year Electric Service Agreement with a utility provider on May 27, 2026, securing up to 65,000 kilovolt-amperes of power for its flagship CLT01 data center campus with a minimum monthly demand charge of $400,000. This long-term operational contract is material to the company's data center infrastructure business and investor assessment of growth capacity and operational sustainability.
View raw filing on EDGAR →
8-K
Other material
confidence 73%
filed 2026-06-01
Item 1.01
Barings BDC entered into a new Credit Support Agreement on May 29, 2026, replacing a prior agreement and providing approximately $11 million in credit support for two legacy portfolio companies. The prior agreement was terminated with a cash settlement of $67,027,611 from the Adviser to the Company, representing a material restructuring of credit support arrangements with explicit downside protection on unrealized investments and fee waivers by the Adviser.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-01
Item 8.01
The Company's Board approved an amendment to expand its common stock repurchase program by an additional $5 million, effective June 1, 2026. While share repurchases can signal management confidence and affect capital allocation, this disclosure does not fit neatly into the more specific event categories (it is not an earnings release, executive change, M&A activity, or other defined material event). The materiality stems from the capital commitment and potential impact on shareholder value and earnings per share, warranting classification as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 70%
filed 2026-06-01
Item 8.01
Dropbox announced authorization of a $900 million share repurchase program on June 1, 2026, representing a material capital allocation decision.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-01
Item 8.01
Sensata announced early tender results for debt tender offers and increased the total cash consideration from $350 million to $400 million across three series of senior notes. While this is a material capital structure event affecting debt obligations, it does not fit cleanly into the more specific categories (ma_activity applies to acquisitions/dispositions, not debt repurchases; covenant_breach requires a default trigger). The increase in tender offer size and announcement of results constitute material disclosure to investors regarding the company's debt management strategy.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-01
Item 8.01
The board determined on May 8, 2026 that the Company cannot complete an initial business combination and will liquidate and dissolve, ceasing operations and redeeming public shares from the trust account. While this is a terminal event for the SPAC, it does not fit the specific "bankruptcy_filing" category (no formal bankruptcy petition) but represents a material liquidation that fundamentally affects shareholder rights and value.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-01
Item 8.01
The Company's board determined on May 8, 2026 that it would not complete an initial business combination and would begin liquidating and dissolving. While this is a terminal event for the SPAC, it does not fit the "bankruptcy_filing" category (no formal bankruptcy petition) nor "going_concern" (which typically addresses doubt about continuation, not a deliberate liquidation decision). The disclosure is material as it fundamentally affects shareholder rights and value, warranting classification as "other_material."
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-01
The filing discloses the Company's quarterly determination of net asset value (NAV) and NAV per Class A unit as of March 31, 2026, including a detailed breakdown of assets ($755.6M), liabilities ($302.5M), resulting NAV of $453.2M, and NAV per unit of $116.25. While NAV disclosures are routine for real estate investment entities, this quarterly valuation is material to investors in assessing the underlying value of their units. However, this does not fit cleanly into the standard 8-K event taxonomy (not earnings, M&A, impairment, litigation, etc.), making "other_material" the most appropriate classification.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-01
Elite Pharmaceuticals disclosed filing an Abbreviated New Drug Application (ANDA) with the FDA for a generic anticoagulant product via Item 7.01 Regulation FD Disclosure. While this is a significant regulatory milestone for a pharmaceutical company that could materially affect future revenue and competitive position, it does not fit neatly into the more specific event categories (not an earnings release, M&A activity, impairment, or executive change). The ANDA filing represents material business development activity that would affect a reasonable investor's assessment of the company's pipeline and prospects.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-01
Item 8.01
Verano announced a 1-for-5 reverse stock split effective June 11, 2026, reducing outstanding shares from 364.4 million to 72.9 million and authorized shares from 5 billion to 1 billion. While reverse splits are material corporate actions affecting share structure and investor holdings, they do not fit neatly into the specific event categories (not M&A, not a restatement, not an impairment, not a delisting risk per se). This is a significant capital structure modification that would affect a reasonable investor's assessment of the company, warranting classification as a material event outside the more specific taxonomy.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-01
Item 5.03
The filing discloses a material strategic transformation involving a company name change (Sharps Technology to SkyAI), ticker symbol changes (STSS to SKYA, STSSW to SKYAW), and a fundamental pivot from legacy operations to an AI-driven financial platform focused on emerging markets. While Item 5.03 typically covers changes in bylaws or articles of incorporation, the substantive disclosure centers on a strategic business transformation with significant operational, geographic, and technological repositioning. This does not fit neatly into the more specific event categories (not an M&A transaction, not an earnings release, not an executive change) but clearly would materially affect a reasonable investor's assessment of the company's direction and risk profile.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-01
The filing discloses the launch of "Vertical Edge," a new edge data center platform representing the completion of a three-platform business model integrating owned data center infrastructure with existing GPU provisioning and financing operations. While this is a significant strategic business development, it does not fit neatly into standard 8-K event categories (not M&A, not an earnings release, not an executive change, impairment, or other defined event type). The announcement of a major new business platform and strategic pivot would be material to investors assessing the company's business model and growth strategy.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-01
Soulpower Acquisition Corporation issued an unsecured promissory note (B Note) for up to $2.5 million to Soulpower Management LLC on May 29, 2026. The note is forgiven upon consummation of the initial business combination but becomes due upon liquidation or default. While this creates a direct financial obligation under Item 2.03, it does not fit cleanly into the standard taxonomy categories—it is neither a covenant breach (no violation disclosed), nor a dilutive issuance (debt, not equity), nor a typical M&A activity. The material nature stems from the $2.5 million obligation and its connection to the sponsor's financing of the SPAC's operations.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-01
MicroVision announced plans to seek shareholder approval for an amendment to its certificate of incorporation to authorize a reverse stock split at a ratio between 1-for-5 and 1-for-15, with the exact ratio to be determined by the Board. While reverse stock splits are sometimes routine, this disclosure involves a material corporate action requiring shareholder approval and would affect the total mix of information available to investors regarding capital structure and potential dilution implications. The filing is solicitation material for the 2026 Annual Meeting of Shareholders, but does not fit neatly into the more specific event categories (it is not an earnings release, executive change, M&A activity, restatement, auditor change, going concern, impairment, shareholder vote results, delisting risk, bankruptcy, covenant breach, cybersecurity incident, dilutive issuance, or material litigation).
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-01
The filing discloses a 1-for-10 reverse stock split effective June 2, 2026, approved by the Board and shareholders (85.4% consent), along with amendments to the Articles of Incorporation reducing authorized shares from 1 billion to 100 million and increasing par value from $0.0001 to $0.001. While reverse splits are routine capital structure events, this disclosure does not fit cleanly into the standard taxonomy categories (not an earnings release, executive change, M&A, impairment, or delisting notice). The event is material to investors as it affects share count, trading symbol temporarily, and capital structure, warranting disclosure under Item 8.01 (Other Events).
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-01
Item 8.01
Summit Therapeutics disclosed results from two clinical trials (AK112-206 Phase II and HARMONi-6 Phase III) for ivonescimab in colorectal cancer via press releases and a scheduled investor conference call. While this represents material clinical trial data that would affect investor assessment of the company's pipeline, it does not fit the specific "earnings_release" category (which typically refers to financial results) nor any other more specific event type. This is a material clinical development disclosure appropriately classified as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-01
Item 8.01
Via Renewables announced the redemption of 1,884,935 shares of Series A Preferred Stock at $25.00 per share (approximately $47.1 million in principal), representing a material capital transaction. While redemptions of preferred stock are routine corporate actions, the magnitude and the fact that it is disclosed in an 8-K Item 8.01 indicates the company views it as material to investors. This does not fit neatly into the more specific event categories (not M&A, not an impairment, not a covenant breach), making "other_material" the most appropriate classification.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-01
Item 8.01
Public Storage disclosed an operating update for same-store facilities covering April 1 through May 28, 2026 and 2025, including key metrics such as average annual contract rent per square foot, churn rates, and occupancy levels, constituting a material event affecting investor assessment of the company's business performance and trends.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-01
Item 3.03
Samsara Inc. completed a reincorporation from Delaware to Nevada effective June 1, 2026, materially modifying shareholder rights by changing the governing law and corporate governance documents. The reincorporation fundamentally altered the legal framework governing the company and its shareholders, as detailed in an Information Statement filed May 11, 2026.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-01
Item 8.01
The Amendment expands the Field of the SPY003 License Agreement from inflammatory bowel disease to all therapeutic uses, subject to time-based dosing restrictions. This materially broadens the Company's development rights and commercial potential for SPY003, affecting the scope of its pipeline and strategic optionality. While not a traditional M&A, restatement, or executive event, the expansion of licensed rights and removal of field restrictions is material to investors assessing the registrant's asset base and development strategy.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-01
Item 1.01
HPE amended its cooperation agreement with Elliott Investment Management to constrain board size to 14 directors through the 2027 Annual Meeting, modifying governance and board composition restrictions.
View raw filing on EDGAR →
8-K
Other material
confidence 85%
filed 2026-06-01
Item 8.01
The disclosure reports that the Phase 2/3 POWER1 study of vormatrigine failed to meet its primary success measure in focal onset seizures, though secondary measures were met. The Company is pausing enrollment in the POWER2 study to reassess the program. For a clinical-stage biopharmaceutical company, a failed primary endpoint in a pivotal Phase 2/3 trial represents a material setback to a key development program that would significantly affect investor assessment of the company's pipeline and prospects. This does not fit neatly into the specific event categories (not a restatement, impairment, or litigation), making "other_material" the appropriate classification.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-01
Item 8.01
Immuneering announced updated Phase 2a clinical trial data for atebimetinib in pancreatic cancer showing a 17.3-month median overall survival versus 8.5 months for standard of care, along with a 36% overall response rate and 82% disease control rate. While this is a clinical trial update rather than a formal earnings release or other specifically enumerated event type, the positive efficacy and safety data for a lead product candidate in a pivotal development stage would materially affect investor assessment of the company's prospects, particularly given the announced Phase 3 trial initiation expected in mid-2026.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-01
Item 7.01
Sable Offshore disclosed a new investor presentation and an updated reserve estimate letter from NSAI (its independent reserve engineer) as of May 31, 2026, along with a scheduled investor conference call. While Item 7.01 is typically used for routine Regulation FD disclosures, the inclusion of updated proved, probable, and possible reserve estimates from the company's independent reserve engineer—a material metric for oil and gas companies—suggests this disclosure carries substantive information that could affect investor assessment. However, the filing does not clearly indicate what specific operational, financial, or reserve changes prompted the update, making it difficult to classify into a more specific event category. The disclosure is material to investors in an energy company but does not fit neatly into the standard taxonomy.
View raw filing on EDGAR →
8-K
Other material
confidence 70%
filed 2026-06-01
Item 1.01
Noble Corp entered into a Third Amendment to its Senior Secured Revolving Credit Agreement on May 29, 2026, increasing total revolving commitments from $550 million to $650 million and extending the maturity from April 2028 to May 2031. This refinancing materially affects the company's liquidity and debt structure.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-01
Item 8.01
Noble Corp announced a planned private offering of $500 million in unsecured senior notes due 2034, a material financing event that affects the company's capital structure and liquidity.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-01
Item 8.01
Noble Finance II LLC, a wholly-owned subsidiary of Noble Corp, priced an $800 million offering of unsecured senior notes due 2034, upsized from the original $500 million. This is a material debt issuance that affects the company's capital structure and financial obligations, but does not fit neatly into the more specific event categories (it is not M&A, a restatement, auditor change, going concern, impairment, delisting, bankruptcy, covenant breach, cybersecurity incident, dilutive equity issuance, or litigation). The debt offering is material to investors as it represents a significant financing event.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-01
Item 7.01
D-Wave announced a multi-year gate-model quantum computing roadmap with specific technical milestones through 2032, including targets for logical qubits and error reduction factors. This disclosure of a material strategic initiative and long-term product development plan does not fit neatly into the standard 8-K taxonomy (not earnings, M&A, executive changes, impairments, or litigation), but would affect a reasonable investor's assessment of the company's technical direction and competitive positioning in quantum computing. The roadmap represents a significant strategic commitment that could influence investor expectations about the company's future commercialization prospects.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-01
Item 7.01
The Company announced successful placement of its 2026-2027 catastrophe excess of loss reinsurance program for its insurance subsidiary. While this is a material operational event for an insurance company (reinsurance placement is critical to risk management and financial stability), it does not fit neatly into the standard 8-K taxonomy. The disclosure is made under Regulation FD (Item 7.01) rather than a more specific Item, and the event involves securing reinsurance capacity rather than earnings, M&A, executive changes, or other enumerated categories.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-01
Item 7.01
Summit Midstream announced an inaugural $35.0 million stock repurchase program on June 1, 2026. While share repurchases can signal management confidence and affect capital allocation, this disclosure does not fit neatly into the standard 8-K taxonomy (not earnings, M&A, executive changes, impairment, covenant breach, or other defined categories). The materiality to investors is moderate—repurchases affect EPS and capital structure—but the event lacks the terminal or crisis-level significance of restatements, going-concern, or bankruptcy filings. Classified as other_material given the $35M authorization and inaugural nature.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-29
Item 7.01
The fund disclosed detailed portfolio composition and metrics as of April 30, 2026, including loan commitments ($1,860M), par value ($1,395M), portfolio company metrics (median EBITDA, leverage ratios, yields), recent loan activity, and industry diversification. This comprehensive financial and operational data is material to investors assessing the fund's asset quality, risk profile, and performance.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-29
Item 8.01
The fund declared a distribution of $0.22 per share and disclosed NAV information as of April 30, 2026 ($24.78 per Common Share, $716 million aggregate), with a caveat that final results may differ materially. This periodic disclosure is material to investors monitoring the fund's distributions and net asset value.
View raw filing on EDGAR →
8-K
Other material
confidence 70%
filed 2026-05-29
Item 7.01
The fund disclosed detailed portfolio composition and metrics as of April 30, 2026, including loan commitments ($497M), par value ($381M), portfolio company metrics, recent loan activity, industry diversification, a declared distribution of $0.19 per share, and NAV of $24.70 per Common Share ($194 million aggregate).
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-29
Item 7.01
The disclosure announces a resubmission of a Biologics License Application (BLA) for RP1 in combination with nivolumab following FDA communications. This represents a material regulatory development for a clinical-stage biopharmaceutical company, as BLA resubmission decisions directly impact the path to commercialization and investor valuation. While not a traditional earnings release, exec change, or M&A event, the regulatory milestone is material to investors assessing the company's pipeline progress and FDA approval prospects.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-29
Item 8.01
The filing discloses a corporate rebranding (name change to "FocalTherics" and ticker change to "FOCL"), combined with a material operational restructuring—the classification of ESWL and Distribution segments as discontinued operations. While the ticker/name change alone might be routine, the discontinued operations announcement signals a significant strategic shift that would materially affect investor assessment of the company's ongoing business and financial trajectory. This combination of rebranding and segment discontinuation does not fit neatly into the more specific event categories and is best classified as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-29
Item 7.01
The disclosure announces Board approval of a quarterly cash dividend payable to shareholders, which is material to investors as it signals capital allocation policy and financial health. However, routine dividend announcements do not fit neatly into the standard 8-K taxonomy categories (earnings_release, exec_departure, etc.), making "other_material" the most appropriate classification for this shareholder-relevant financial event.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-29
Item 8.01
The company formed a Special Committee to review strategic alternatives, including financing, recapitalization, equity issuance, asset sales, and debt restructuring, with Houlihan Lokey retained as financial advisor. This broad mandate signals potential material corporate changes that could affect the company's financial condition and strategic direction.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-29
Item 5.03
The filing discloses a one-for-eight reverse stock split and reduction in authorized shares from 150,000,000 to 18,750,000, approved by stockholders on May 19, 2026 and effective May 29, 2026. While this is a structural capital event that affects all shareholders proportionately and is material to investors (affecting share count, trading basis, and equity compensation plans), it does not fit neatly into the more specific event categories. Reverse stock splits are typically routine corporate actions undertaken to maintain listing compliance or improve stock price perception, and the disclosure emphasizes no change in percentage ownership or par value. This is classified as other_material rather than a more specific category because the taxonomy lacks a dedicated reverse-split classification.
View raw filing on EDGAR →
8-K
Other material
confidence 73%
filed 2026-05-29
Item 5.03
The Company implemented a 1-for-10 reverse share split effective May 28, 2026, approved by shareholders on May 5, 2026, through an amendment to its Memorandum of Association filed with the Cayman Islands Companies Registry. In connection with this capital restructuring, warrant terms were materially modified, including a reduction in the number of shares issuable per warrant to 1/10th and a ten-fold increase in exercise price to $15,525.00, proportionally adjusting warrant holders' economic rights.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-29
Item 8.01
Heritage Insurance announced successful placement of its 2026-2027 catastrophe excess-of-loss reinsurance program for its three insurance subsidiaries. For an insurance holding company, securing reinsurance capacity is material to investors as it directly affects the company's ability to manage catastrophic risk exposure and maintain underwriting capacity. However, the disclosure is routine operational news rather than a discrete event type (M&A, covenant breach, impairment, etc.), warranting classification as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-29
Item 7.01
The fund disclosed Transactional NAV per Unit as of April 30, 2026 (Class I: $29.08, Class S: $28.75, Class D: $28.98) and aggregate fund NAVs ($5.0 billion for BXINFRA, $272.0 million for BXINFRA Lux), establishing the pricing basis for unit transactions and reflecting the fund's asset valuation.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-29
Item 8.01
Palomar announced successful completion of reinsurance programs incepting June 1, 2026, including $421 million of incremental earthquake limit and increased full-year 2026 adjusted net income guidance, reflecting expanded reinsurance capacity and improved risk profile.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-29
Item 7.01
The filing discloses a declared distribution to shareholders of $0.1560 per share (gross) across three share classes, payable on June 3, 2026. While distribution declarations are routine for REITs and real estate investment trusts, this disclosure under Item 7.01 (Regulation FD Disclosure) rather than a standard earnings release or distribution announcement suggests it may carry material significance to investors assessing dividend sustainability and cash flow. However, the event does not fit cleanly into the more specific taxonomy categories (earnings_release, which typically includes full financial results; or other standard event types), making "other_material" the most appropriate classification.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-29
Item 8.01
The filing discloses a distribution declaration for multiple share classes with specific per-share amounts ($0.0423 gross), record and payment dates, and notably waives the stockholder servicing fee on Class D shares in perpetuity. While distribution declarations are routine for REITs, the perpetual waiver of Class D servicing fees is a material change to the fee structure that affects shareholder economics and is not a standard administrative disclosure.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-29
Item 8.01
Chase Issuance Trust completed a $1.25 billion securitization of credit card receivables on May 28, 2026, issuing Class A(2026-1) notes as part of the CHASEseries. While this is a significant financing transaction, it does not fit cleanly into the M&A activity category (which typically covers acquisitions, dispositions, mergers, or changes of control) nor any other more specific event type. The disclosure is material to investors as it represents a substantial capital markets transaction and refinancing activity, but the securitization structure and credit risk retention mechanics do not align with standard M&A or dilutive issuance classifications.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-29
Item 7.01
The filing discloses a declared distribution of $0.04326 per share (net of fees) across multiple share classes, payable June 10, 2026. While distribution declarations are routine for REITs and typically immaterial administrative disclosures, this Item 7.01 Regulation FD Disclosure suggests the company deemed the distribution announcement material enough to file an 8-K. The specific per-share amounts and payment details would affect investor assessment of yield and cash flow, making it material to shareholders, though it does not fit neatly into the standard event taxonomy.
View raw filing on EDGAR →